RSV vaccine (National Institute of Allergy and Infectious Diseases)

Respiratory Syncytial Virus (RSV) vaccines are designed to prevent severe illness caused by the RSV, a common respiratory virus that can lead to serious infections, particularly in infants, older adults, and immunocompromised individuals. The primary mechanism of action for many RSV vaccines involves stimulating the immune system to produce antibodies against the RSV fusion (F) protein, especially in its prefusion conformation. The F protein is crucial for the virus to infect host cells, and stabilizing it in its prefusion form allows for a more potent immune response. These vaccines aim to block the virus's ability to fuse with host cells, thereby preventing infection and reducing the risk of hospitalization or death. Development efforts have included various approaches, such as protein subunit vaccines, mRNA-based vaccines, and live-attenuated viruses. Several RSV vaccines have been approved or are in late-stage clinical development by companies like GSK, Pfizer, and Moderna.

Other names

RSV vaccine formulation 1